Background: Urticaria or hives is a common skin condition usually resolves within a few hours and always by 24 hours. It is mediated by aberrant release of histamine and other inflammatory mediators from mast cells and basophils1. The therapeutic approach should be based on elimination or avoidance of the cause or trigger/stimulus, symptomatic drug treatment by reducing mast cell mediator release and inducing tolerance. Oral Bepotastine besilate is non-sedative, selective H1-R antagonist. Aim: To study the efficacy and tolerance of oral Bepotastine besilate in respect of wheal, pruritus, sedation and effectiveness in chronic urticaria patients. Methodology: All adult Patients attended out-patient department of our dermatology department, who had a history of wheals, erythema more than 6 weeks with pruritis were included. Pregnant and lactating women were excluded. After clinical diagnosis Oral bepotastine 10 mg twice daily was started and response ( pruritus, wheals, drug effectiveness and sleepiness ) was assessed by urticaria activity score (UAS), Medication effective score (MAS), Sedation scale in a predesigned performa on day 0,14 and 28. Results: The majority of patients showed significant improvement in pruritus and wheal scores as compared to baseline, starting from end of the second week visit. Among 45 patients; 38 had no sedation and 7 had mild drowsiness. Nine patients achieved complete relief. Conclusion: Bepotastine 10 mg twice daily is well tolerated, effective and non-sedative antihistamine drug for the treatment of chronic urticaria